摘要
目的对比观察FAM及FAM辅加ATRA方案对胃癌术后患者的疗效。方法将62例胃癌根治性手术(D2、D3)后患者随机分为FAM+ATRA组及FAM组。结果FAM+ATRA组术后第1、2、3年的肿瘤复发转移率分别为16.1%,38.7%和67.7%;FAM组分别为25.8%,54.8%和74.2%。术后FAM+ATRA组1、2、3年生存率分别为93.5%、74.2%和38.7%;FAM组分别为80.7%、61.3%和35.5%。2组术后第1、2年的肿瘤复发转移率和患者1、2年生存率比较均有显著性差异(P<0.05),2组术后第3年肿瘤复发转移率和患者3年生存率比较无显著性差异(P>0.05)。结论FAM辅加ATRA治疗能有效提高胃癌术后患者的近期疗效及1、2年生存率。
Objective To evaluate the efficacy of FAM and FAM+ATRA chemotherapy for patients with postoperative gastric cancer.Methods 62 cases who received D2 or D3 gastrectomy were randomly divided into two groups to receive either FAM chemotherapy or FAM+ATRA chemotherapy.Results The 1-,2- and 3-year recurrent rates were 16.1%,38.7% and 67.7% for FAM+ATRA group,25.8%、54.8% and 74.2% for FAM group.The 1-,2- and 3-year survial rates were 93.5%、74.2% and 38.7% for FAM+ATRA group,80.7%、61.3% and 35.5% for FAM group.The 1-,2-year recurrent rate and suruvial rate were significantly different between the two groups(P<0.05).The difference was not significant in 3-year recurrent rate and sruvial rate between two groups(P>0.05).Conclusion FAM+ATRA can improve the short term therapeutic efficacy and increase the 1-,2-year survival rate.
出处
《实用癌症杂志》
2005年第2期166-168,共3页
The Practical Journal of Cancer
